Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe.1-3 As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.
De Hert M, Detraux J. The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication. JAMA Psychiatry. 2018;75(8):771–772. doi:10.1001/jamapsychiatry.2018.1080
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: